

# An overview on Actinomycetes: A source of antimicrobial compounds

Shradha Basi-Chipalu\*, Pallavi Sthapit\*

\*Department of Microbiology, Tri-Chandra Multiple Campus, Ghantaghar, Kathmandu, Nepal.

**Abstract:** Actinomycetes are aerobic, spore forming Gram positive bacteria. Their structure has substrate and aerial mycelium. They are the most abundant microorganisms in the soil, producing earthy smell in ploughed soil. Actinomycetes were explored because they produce important secondary metabolites that plays important roles in many physiological, cellular and biological processes. For example, antibiotics, biopesticide agents, plant growth hormones, antitumor compound, antiviral agents, pharmacological compounds, pigments, enzymes, etc. Among many, *Streptomyces* sps. was the most explored and useful soil actinomycetes. In recent time, new strains of actinomycetes were isolated from extreme environment because of their wide range of application in pharmaceutical, food, agriculture and environmental industries. Therefore, this review is aimed on the use of Actinomycetes as a potential source for novel antimicrobial compounds and highlight on its application in various sectors like medicine, biotechnology, industries, agriculture and research.

**Keywords:** Actinomycetes; Antibiotics; Streptomycetes; Bioremediation; Enzymes.

## Introduction

Antimicrobial compounds are those chemical agents produced by microorganisms as secondary metabolites. They are widely available in nature and they play a role to regulate microbial population in soil, water, etc<sup>1</sup>. Those compounds can be categorized as antibacterial (or antibiotics) that act against bacteria and antifungal which act against fungi. Antimicrobial substances are produced by many microbes, higher plants and animals<sup>2</sup>. A number of antimicrobials currently used in medicine are derived from the microbial origin.

The discovery of Penicillin by Alexander Fleming in 1828 was considered to be golden era of medicine. Antibiotics have saved many lives from bacterial infections. Most of the antibiotics till date are produced by Actinomycetes followed by other bacteria such as Bacillus. They are considered as one of the important class of microbes that can produce different classes of antibiotics. They are also a good resource for many natural compounds which had a

great potential uses in diverse purposes<sup>3</sup>. Around 80% of antibiotics are derived from the genus *Streptomyces* and rare actinomycetes, such as *Actinomadura*, and only the 20% is produced by fungal species.

Actinomycetes are the prokaryotic organism and represent one of the largest taxonomic units among the 18 major lineages currently recognized within the domain bacteria. They are generally anaerobic and have mycelium in a filamentous and branching growth pattern. They are soil organism<sup>3</sup>. They are Gram positive bacteria which can form rod or coccoid shape, while some can form spores on aerial hyphae<sup>4</sup>. Gentamycin, Kanamycin, Streptomycin, Tobramycin, etc are some examples of antibiotics produced by Actinomycetes<sup>5</sup>.

The use and misuse of antibiotics had resulted in emergence of resistant strains. For example, methicillin resistant *S. aureus* (MRSA). Then after, vancomycin was used to treat infections due to methicillin resistant *S.*

**Author for correspondence:** Shradha Basi-Chipalu, Department of Microbiology, Tri-Chandra Multiple Campus, Ghantaghar, Kathmandu, Nepal.

Email: shradhabc@hotmail.com; <https://orcid.org/0009-0006-5023-1917>

Received: 22 July, 2025; Received in revised form: 26 Dec, 2025; Accepted: 3 Jan, 2026.

Doi: <https://doi.org/10.3126/sw.v19i19.95594>

*aureus*, the most common cause of hospital acquired infections, developed resistance to methicillin and several other antibiotics. The over use of vancomycin to treat MRSA, vancomycin resistant *Enterococcus faecium* (VRE) appeared. In addition, there are many Gram negative pathogens such as *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and Enterobacteriaceae which are resistant to many antibiotics<sup>7</sup>. Although there are many antibiotics available, there is still a need for discovery of new types of antibiotics to solve the problem of multi drug resistant (MDR) among pathogenic bacteria. There are a few antimicrobial compounds, such as antimicrobial peptides, probiotic bacteria, and bacteriophages which are now considered as alternatives to antibiotics. Thus, this review is aimed to explore Actinomycetes as a producer of antimicrobial compounds.

### Actinomycetes

Actinomycetes are most widely distributed microorganisms in nature and constitute significant component of microbial population in soil and are important source of antibiotics, enzymes and bioactive products<sup>8</sup>. *Actinomycetes* belong to the order of Actinomycetales, whose phylum is Actinobacteria, which is the largest taxonomic unit within the bacteria domain. This phylum comprises Gram positive bacteria with high guanine-cytosine (G + C) content in their DNA, such as 51% in some Corynebacteria and more than 70% in *Streptomyces* and *Frankia*<sup>9</sup>. According to Bergey's manual of Determinative Bacteriology, the order Actinomycetales are divided into eight diverse families: Actinomycetaceae, Mycobacteriaceae, Frankiaceae, Actinoplanaceae, Dermatophilaceae, Nocardiaceae, Streptomycetaceae, and Micromonosporaceae<sup>10</sup>. While, the latest edition of Bergey's Manual, from 1994 has divided the order actinomycetales into three families, as, Mycobacteriaceae, Actinomycetacea and Streptomycetacea. The first family comprise of the genus *Mycobacterium*, which is beyond the scope of this treatise. The second and third family comprises the true Actinomycetes. The genera *Nocardia* and *Actinomyces* fall into second family, and the genera *Streptomyces* and *Micromonospora* belong to the third.

Another genus has been recently added, *Thermoactinomyces*, which include certain thermophilic forms.

Actinomycetes are heterotrophic organisms and thus, they depend on various organic materials for their source of energy or food. They decompose various organic materials in their surroundings. To break down these complex compounds they produce a number of enzymes including cellulases and keratinases. They participate in turn-over of soil components, especially in the transformation of organic compounds<sup>11, 12, 13, 14</sup>. Since they can decompose complex mixtures of polymers in dead plants, animals and fungal material<sup>15, 16, 17</sup>, they have important role in soil degradation.

Secondary metabolites obtained from Actinomycetes provide a potential source of many novel compounds with antibacterial, antitumour (doxorubicin and bleomycin), antifungal (e.g., amphotericin B and nystatin), antiviral, antiparasitic and other properties viz. immunosuppressives (FK-506 and rapamycin), insecticides (spinosyn A and avermectin B), herbicides (phosphinotricin)<sup>18,19, 20</sup>. Antibiotics are the best-known products of Actinomycetes<sup>21, 22</sup>. It is known that the actinomycetes are the source of some 61% of all microorganism-derived bioactive substances discovered so far<sup>23</sup>. Around two-thirds of all known antibiotics are produced by actinomycetes, *Streptomyces* being the predominant one<sup>9</sup>. Some examples of antimicrobial compounds produced by actinomycetes are streptomycin (*Streptomyces griseus*), chloramphenicol (*S. venezuelae*), tetracycline (*S. rimosus*), erythromycin (*Saccharopolyspora erythraea*), leucomycin (*S. kitasatoensis*), vancomycin (*S. orientales*), and gentamicin (from *M. purpurea*)<sup>24</sup>.

### Antimicrobial compounds from Actinomycetes

Actinomycetes have played a significant role in producing variety of antibiotics<sup>25</sup>. Approximately 80% of antibiotics till date are form Actinomycetes, especially from genera *Streptomyces* and *Micromonospora*<sup>26, 27</sup>. A total of 10,100 different bioactive metabolites have been derived from Actinomycetes<sup>28, 29</sup>. Among them, most of the secondary

metabolites are potent antibiotics<sup>30</sup>. The antibiotics produced from Actinomycetes are classified into several classes on the basis of chemical structure: i) beta-lactams (eg. Cephalosporins)<sup>31</sup>, ii) macrolides (eg. Erythromycin) and tetracyclines<sup>32</sup>, iii) aminoglycosides (eg. Streptomycin)<sup>33</sup>, iv) ansamycins (eg. Rifampin)<sup>34</sup>, v) anthracyclines (eg. Doxorubicin)<sup>35</sup>. Some of the antibiotics produced by Actinomycetes are described below:

### **Cephalosporins**

Cephalosporins are beta lactam antibiotics produced by *Streptomyces clavuligerus*<sup>31</sup>, and are one of the most widely prescribed antibiotic clinically<sup>36</sup>. It is a semisynthetic bactericidal drug which disrupts the synthesis of peptidoglycan layer of bacterial cell wall. It is active against both Gram positive and Gram negative bacteria. Cephalosporin is used to treat bacterial infections caused by bacteria like *Escherichia coli*, *Klebsiella sp.*, *Proteus sp.*, etc.<sup>37, 38</sup>.

### **Tetracyclines**

The tetracycline was first derived as natural product from actinomycetes by fermentation process. Chlortetracycline was produced by *Streptomyces aureofaciens*<sup>39</sup> which was available in market as Aureomycin. In late 1980s, a semisynthetic derivative of tetracycline was discovered with improved activity against emerging multidrug resistant (MDR) Gram positive and Gram negative pathogens<sup>40</sup>. Lately, there are two new tetracycline derivatives have been discovered, eravacycline<sup>41,42</sup> and omadacycline<sup>43</sup> respectively at Tetrphase Pharmaceuticals and Paratek Pharmaceuticals.

### **Macrolides**

Macrolide antibiotics are compounds that occur naturally (Erythromycin), later they are modified to make semisynthetic and synthetic (Azithromycin, clarithromycin, dirithromycin, roxithromycin, josamycin, kitasamycin, spiramycin, flurithromycin, rokitamycin, mycinamycin, mirosamycin, oleandomycin and tylomysin)<sup>44</sup>. Macrolides are made of large macrocyclic lactone ring with 12 to 16 atoms attached to one or more sugar moieties by glycosidic bonds<sup>45</sup>. Most of the

macrolides are produced from various species of *Streptomyces*. They inhibit bacterial growth by targeting on protein synthesis<sup>46</sup>.

### **Streptomycin**

Streptomycin is the first discovered aminoglycoside antibiotic which was isolated from *Streptomyces griseus*<sup>44</sup>. It is used to treat aerobic Gram negative bacterial infections such as brucellosis, tularemia, plague, tuberculosis (with isoniazid, pyrazinamide and rifampin) and endocarditis (with beta-lactam antibiotics)<sup>45</sup>. For pulmonary tuberculosis, streptomycin is an alternative therapy, second to RIPE (rifampin, isoniazid, pyrazinamide and ethambutol) therapy<sup>46</sup>. The wide spectrum of activity of streptomycin against Gram negative and Gram positive bacteria is diminished due to the development of antibiotic resistance. Enterobacteriaceae and most Streptococci are generally resistant of streptomycin.

### **Rifampicin**

It is a group of semisynthetic derivatives of an antibiotic produced by *Nocardia mediterranea*. Rifampin is used to treat diverse mycobacterial infections and Gram positive bacterial infections. Rifampin inhibits DNA-dependent RNA polymerase (RNAP). The U.S. Food and Drug Administration (FDA) approved rifampin to treat active and latent tuberculosis (TB)<sup>47</sup> and to eliminate asymptomatic carriers of *N. meningitides*<sup>48</sup>. To reduce the development of resistant strains, rifampin is combined with other antimicrobial agents to treat infections caused by *S. aureus* and for cerebrospinal fluids (CSF) shunts and drains<sup>49</sup>.

### **Anthracycline**

Anthracyclines are the most effective chemotherapeutic agents for the treatment of various types of cancers. For example: leukemia, lymphomas, breast, stomach, uterine, ovarian, bladder and lung cancers<sup>50</sup>. Anthracyclines are extracted naturally from *Streptomyces peucetius*. and consist of different types like, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone and valrubicin<sup>51</sup>. The action of anthracyclines is due to their interaction with

topoisomerase-II. The complex formed prevents the relegation of the ds-DNA breaks which causes apoptotic cell death.

## Applications of Actinomycetes and its product

### 1. Application in pharmaceuticals

Actinomycetes produce about 45% of bioactive compounds having antagonistic activity which have application in the food, agriculture, medicine, pharmacy, etc.<sup>52</sup>. Among them, 34% compounds were produced by *Streptomyces* and 11% compounds were produced by other actinomycetes<sup>53</sup>. The scientific community and public-private partnerships should discover new sources of antimicrobial agents to control pathogens<sup>53</sup>.

#### i. Antibacterial compounds:

*Streptomyces* sp. XMA39 produced four medermycin-type naphthoquinones, strepoxepinmycins A-D (1-4), and medermycin<sup>5</sup>. *Streptomyces* sp. SM01 produced novel antimicrobials, picolinamycin (SM1). It is more active against Gram positive bacteria than Gram negative bacteria. Also, it is effective against many multidrug resistance (MDR) strains, like methicillin-resistant strains of Staphylococci and Enterococci and MDR strains of *S. aureus*<sup>54</sup>.

*Streptomyces* sp. SNO280 produced various important compound, such as indole derivative chloroindole, diketone streptoone A, ketonic acids streptoones B and C, and a macrolide antibiotic X-14952B. Streptoone A showed antibacterial activity against *Clavibacter michiganensis*. Streptoone B showed antifungal activity against *Phytophthora capsici*. These molecules helped in the treatment and management of the phytopathogens<sup>55</sup>.

#### ii. Antifungal compounds:

*Streptomyces* species are the most important genus because they produce about 75% bioactive microbial metabolites<sup>56</sup>. Guan and coworkers in 2016 showed that *Streptomyces songpinggouensis* was active against the fungi *S. sclerotiorum*, *C. cassicola*, *A. solani*, *C. lunata*, *S. turcicaf*, *H. maydis*, *F. oxysporum*, *C. orbiculare* and *P.*

*infestans*<sup>57</sup>.

*Streptomyces albus* strain CAI-21 and its active metabolite organophosphate can control charcoal rot disease in sorghum caused by *Macrophomina phaseolina*<sup>58</sup>.

*Streptomyces morookaense* AM25 produced a novel peptide gloeosporiocide, having cyclized cysteins to form three thiazoles. It can be used as biocontrol agent and producers of antifungal activity<sup>59</sup>.

#### iii. Antitumor compounds:

Marine actinomycetes are good source of antitumor drugs. For example, *Micromonospora*, *Salinispora* and *Verrucosipora*. The marine *Streptomyces* sp. shell-016 was isolated from a shell sediment sample. It produced four novel bioactive tetrahydroanthra-gama-pyrone compounds called shellmycin A-D (1-4)<sup>60</sup>. These compounds exhibited cytotoxic activity against five cancer cell lines. Also, the putative biosynthetic pathways of these compounds were discussed according to their structure-activity relationship<sup>63</sup>.

Bioactive compounds with binding affinity to DNA as a target molecule to fight against cancer cell is very important. *Microbacterium* sp. RP581 produced Microindoline 581 which can cause double-strand breaks through binding to the DNA<sup>62</sup>. The selective action of Microindoline 581 in killing HepG2 cells might be due to specific metabolism in the cells as a precursor<sup>62</sup>.

#### iv. Antiviral compounds:

Moreover, actinomycetes inhibit many viruses like hepatic C virus (HCV), influenza A virus (IAV), human immunodeficiency virus (HIV), herpes simplex virus (HSV) and epidemic diarrhea virus (EDV). The antiviral compounds are labyrinthine, chartreusin, xiamycin, butanolides and antimycins<sup>62</sup>.

*Streptomyces* sp. CPCC 200267 produced two cyclic thiopeptides, geninthiocins E and F, four geninthiocin derivatives, geninthiocins A, B, C and val-geninthiocin. Geninthiocin E, val-geninthiocin, geninthiocin A and B exhibited anti-influenza A virus activities with the IC<sub>50</sub> values of 28.7, 15.3, 7.3 and 18.3 $\mu$ M, respectively<sup>63</sup>.

*Streptomyces* sp. AM-2504 produced two new antibiotics, called virantmycin B and C. They contain a tetrahydroquinoline and an indoline, respectively and also a hydroxycyclopentenone moiety. Both compounds showed a weak antibacterial and antifungal activities. Virantmycin B showed antiviral activity against the dengue virus<sup>64</sup>.

v. Other compounds:

Actinomycetes also produce antiparasitic agents like valinomycin, butanolides, avermectins and milbemycins which inhibit *Leishmania* sp., *Trypanosoma* sp. and helminths<sup>65</sup>.

Actinomycetes also produce therapeutic immune-suppressants or drug immunoconjugates such as rapamycin, tacrolimus and sirolimus<sup>66</sup>. Actinomycetes also produce antioxidant compounds like hexaricins, polyketides, pyrazoloquinolines and agelolines, protecting from infections and degenerative diseases<sup>67</sup>.

Furthermore, actinomycetes produce antioxidant, anti-inflammatory, immunosuppressive, antiparasitic and cytotoxic compounds. Anticancer drugs like anthracyclines, bleomycin, mitomycin, enediyne, etc are also produced from actinomycetes<sup>59</sup>.

Actinomycetes also produce antioxidant compounds like hexaricins, polyketides, pyrazoloquinolines and agelolines, protecting from infections and degenerative diseases<sup>67</sup>. Actinomycetes also produce therapeutic immune-suppressants or drug immunoconjugates such as rapamycin, tacrolimus and sirolimus<sup>66</sup>.

## 2. Applications in food and other industries

*Streptomyces* sps are the most important enzyme producer actinomycetes. They produce enzymes such as chitinase, proteases, cellulases, pectinases, L-glutaminase, amylases, etc<sup>68</sup>. Microbial enzymes are generally safe, stable and functional at different temperature, pH and salinity<sup>69</sup>.

Heat stable enzymes are very useful because they reduce the contamination by mesophilic microorganisms and they also improve the efficiency of substrate degradation<sup>70</sup>. Wu and colleagues (2018) showed that *Streptomyces thermoalkaliphilus* produce alkaline cellulose with potential carb-

-oxymethyl cellulose degrading activity<sup>71</sup>.

Lipases are useful in processing of oils and fats, cosmetics and detergents because lipases catalyse the hydrolysis of lipids<sup>72</sup>. Keratinases are useful in the recycle of chicken feathers and nails because keratinases catalyse the hydrolysis of keratin<sup>69</sup>. Keratinases are produced by *Streptomyces* sp, *Saccharomonospora* sp, *Nocardioideis* sp, *Nocardioopsis* sp and *Nonomuraea* sp. Proteases have application in milk coagulation, clarification of fruit juices, paper industry<sup>73</sup>. Pectinases are used in fruit-based foods and beverages, textile, paper and pulp industry, agriculture sector, etc.<sup>74</sup>. L-asparaginase enzyme is produced by soil actinomycetes such as *Streptomyces griseus*, *S. karnatakensis*, *S. albidoflavus* and *Nocardia* sp.<sup>75</sup> and are used not only in food industry but are used for bone marrow treatment and stem cell transplant as well (Table 1). Important antibiotic and enzyme producers are *Streptomyces scabriformis*, *S. sparsogenes*, *S. misakiensis*, *S. cirratus*, *S. lincolnensis*, *S. endophyticus*, *S. chartreusis* and *S. alboniger*<sup>76,77</sup>.

## 3. Application in Agricultural sector

Actinomycetes are used for sustainable agriculture to produce biofertilizers and biocontrol agents<sup>78</sup>. Biofertilizer is a substance that contains living microorganisms, which colonize the rhizosphere or plant interior and helps to release nutrients to the host plant<sup>79</sup>. Biocontrol agents are used to control plant diseases by releasing secondary release nutrients to the host plant<sup>79</sup>. Biocontrol agents are used to control plant diseases by releasing secondary metabolites<sup>80</sup>. For example, *Streptomyces griseoviridis* is a biocontrol agent. It is effective against plant pathogens together with *Alternaria brassicicola* Wiltsh., *Botrytis cinerea* Pers., *Fusarium avenaceum* Sacc., *F. culmorum*<sup>80</sup>. Actinomycetes are very beneficial for soil and plant health, because they produce enzymes, increases soil fertility, fix nitrogen, degrade organic matter, kill pests and bioremediate soils<sup>78</sup>.

*Streptomyces* is the most useful actinomycetes in soil. These fix nitrogen and solubilize phosphate, excrete secondary metabolites like antioxidants, antimicrobials and enzymes in soil<sup>78,81</sup>. *Frankia* family of actinomycetes makes symbiotic relation with nonleguminous plants to fix

**Table 1: The applications of enzymes produced from actinomycetes<sup>77</sup> (modified from Sharma, 2014).**

Enzymes	Applications
Amylase	Used in fermentation, in food industry, in textile and paper industry
Catalase	Used as an antioxidant, in cold sterilization of beer, in dairy industry
Cellulase	Used in biomechanical pulping, in laundry, in animal feed industry
L-asparaginase	Used in bone marrow treatment, in stem cell transplant, in treatment of acute leukemia
Lipase	Used in oleochemical, in detergent industries, in diagnostic settings, in pharmaceutical industries
Urease	Used in wine industry, in analysis in blood and urine, in analysis of heavy metal content in waste water and soil
Protease	Used as antiinflammation, to protect against clot, in cancer treatment
Chitinase	Used in plant resistant against fungal pathogen, in drug delivery and wound healing, in biochemical industry
Keratinase	Used in poultry industry

nitrogen which is used by the host and other nearby plants<sup>82</sup>. Actinomycetes from the genus *Micromonospora*, *Nocardia*, *Actinomadura* sp, *Rhodococcus* sp, *Actinoplanes*, *Microbiospora* sp and *Streptosporangium* sp produce phosphatase enzymes. They mineralize organic phosphate which will be available for plants<sup>83</sup>.

Actinomycetes are characterized by plant growth-promoting rhizobacteria (PGPR) in rhizosphere<sup>84</sup>. Actinomycetes improve nutrients and minerals, synthesize plant growth regulators and inhibit pathogens. Actinomycetes are important microorganisms in producing siderophores in soil (Table 2). Siderophores are chelate agents of ferric ion and reduce ferric ions to ferrous ions which are easily absorbed by microorganisms<sup>85</sup>. Actinomycetes produce plant growth hormone indole-3-acetic acid (IAA). It is an important auxin which helps in basic cellular processes such as cell division, elongation and differentiation. It also decreases the root length and increases the root hair to enhance nutrient absorption<sup>86</sup>. Actinomycetes produce insecticidal compounds which control housefly *Musca domestica* and kill mosquito *Culex quinquefasciatus*<sup>87</sup>. They also act against the fungus *Phytophthora* sp,<sup>88</sup>. *Streptomyces indiaensis* showed antifungal activity against *F. oxysporum*, *A. fumigatus*, *A. flavus*, *A. niger* and *H. graminum*<sup>89</sup>. The antifungal activity of *Streptomyces* is due to the production of enzyme chitinase (Table 2)<sup>90</sup>.

#### 4. Environmental purposes and other uses

Actinomycetes are the predominant microorganisms in soil that recycle organic matter<sup>91</sup>. They decompose the cellulose and lignin of wood and paper and the chitin of the exoskeletons of insects. In composting, thermophilic and thermotolerant actinomycetes cause decomposition of organic matter.

They are used for soil bioremediation (Table 3) because it is environment friendly and cheap<sup>92</sup>. In bioaugmentation, microorganisms are used to reduce, remove or transform contaminants present in the soil<sup>93</sup>. *Promicromonospora* sp. UTMC 2243 removed 96.5% residual cadmium<sup>94</sup>. The actinomycetes *Rhodococcus* removed 93% of the fungicide carbendazim from soils in 14 days as shown in table 4<sup>95</sup>. Different strains of actinomycetes produce different and new useful antibiotics so new stains are isolated and screened<sup>30</sup>.

Actinomycetes produce pigments such as blue, violet, red, yellow, green, brown and black<sup>96</sup>. A blue pigment actinorhodin was produced by *Streptomyces coelicolor*, *S. violaceusruber* and *S. lividans*. It is applied as an antibiotic

against Gram positive bacteria, as a pH indicator and in food industry for making beverages, desserts, etc and in cosmetic industries<sup>97</sup>. *Streptomyces* species produced yellow antibiotic called 4-hydroxynitrobenzene which was active against *Bacillus subtilis* and *Shigella shiga*. These pigments are safe for human utilization and easy to produce<sup>98</sup>. El-Sheekh colleagues reported the production of biodiesel from *Streptomyces coelicolor* (Table 3) which had higher heating value than algal biodiesel<sup>99</sup>.

**Table 2: The uses of actinomycetes in agriculture<sup>68</sup> (modified from Nazari et al., 2022).**

Actinomycetes	Applications
<i>Streptomyces</i> sp.	Inhibited the mycelial growth of the fungus <i>Phytophthora infestans</i> that causes late blight in potato cultivation.
<i>Streptomyces</i> sp.	Increased minerals, vitamins and antioxidants in seeds and increased nitrogen and nutrients in the soil
<i>Streptomyces</i> sp., <i>Nocardioopsis</i> sp.	High production of ammonia and indole acetic acid, and inorganic phosphate was dissolved
<i>Streptomyces</i> sp.	Production of chitinase and pest control
<i>Streptomyces</i> sp.	Antifungal potential and better crop quality
<i>Streptomyces</i> sp.	All isolates produced siderophore, and two novel <i>Streptomyces</i> produced enterobactin and heterobactin.

## Conclusion

The actinomycetes are immensely used in various fields. It has been an important source of biologically active secondary metabolites. Actinomycetes produce industrially valuable compounds. Studies have focused on antimicrobial potential, enzymes production, agricultural uses, bioremediation, biofuels and pesticides degradation

**Table 3: The environmental applications of soil actinomycetes<sup>68</sup> (modified from Nazari et al., 2022).**

Actinomycetes	Applications
<i>Streptomyces coelicolor</i>	Bioethanol production
<i>Rhodococcus qingshengii</i>	Carbendazim bioremediation
<i>Streptomyces coelicolor</i>	Biodiesel production
<i>Streptomyces torulosus</i>	Natural dyes
<i>Streptomyces</i> , <i>Saccharothrix</i> , <i>Streptosporangium</i> , <i>Nonomuraea</i> , <i>Promicromonospora</i>	Heavy metal bioremediation

*Streptomyces* was the genus with the highest incidence among soil actinomycetes and the most exploited for different uses. Actinomycetes are the most promising industrial microorganisms because they are found in large numbers and can tolerate many substances and environments.

## References

- Sethi, S., Datta, A., Gupta, B. L. & Gupta, S. 2013. Optimization of cellulase production from bacteria isolated from soil. *International Scholarly Research Notices*. **2013**(1): 985685. Doi: <https://doi.org/10.5402/2013/985685>
- Thompson, R. L. & Wright, A. J. 1998. General principles of antimicrobial therapy. *Mayo Clinic proceedings*. **73**(10): 995–1006. Doi: <https://doi.org/10.4065/73.10.995>
- Grasso, L. L., Chillura-Martino, D. & Alduina, R. 2016. Production of antibacterial compounds from actinomycetes. *Actinobacteria-basics and biotechnological applications*. **7** (2016): 177-98. Doi: <https://doi.org/10.5772/61525>
- Atlas, R. M. 1997. *Principles of Microbiology*. Second edition, WCB McGraw-Hill, New York.
- De Simeis, D. & Serra, S. 2021. Actinomycetes: A never-ending source of bioactive compounds - An overview on antibiotics production. *Antibiotics*. **10**(5): 483. Doi: <https://doi.org/10.3390/antibiotics10050483>
- Rubin, M., Hathorn, J. W., Marshall, D., Gress, J., Steinberg, S. M. & Pizzo, P. A. 1988. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. *Annals of internal medicine*. **108**(1): 30 – 35.

- Doi: <https://doi.org/10.7326/0003-4819-108-1-30>
7. Livermore, D. M. 2004. The need for new antibiotics. *Clinical Microbiology and Infection*. **10**: 1-9.  
Doi: <https://doi.org/10.1111/j.1465-0691.2004.1004.x>
  8. Barakate, M., Ouhdouch, Y., Oufdou, K. H. and Beaulieu, C. 2002. Characterization of rhizospheric soil streptomycetes from moroccan habitat and their antimicrobial activities. *World J. Microbiol. Biotechnol.* **18**: 49-54.  
Doi: <https://doi.org/10.1023/a:1013966407890>
  9. Barka, E.A., Vatsa, P., Sanchez, L., Gaveau-Vaillant, N., Jacquard, C., Klenk, H.-P., Clément, C., Ouhdouch, Y. and van Wezel, G.P. 2016. Taxonomy, physiology, and natural products of actinobacteria. *Microbiol. Mol. Biol. R.* **80**:1-43.  
Doi: 10.1128/MMBR.00019-15.
  10. Buchanan, R. E. & Gibbons, N. E. 1974. *Bergey's Manual of Determinative Bacteriology*. 8th ed. Williams & Wilkins Co., Baltimore .
  11. Konova, M. M. & Broadbent, F. E. 1970. Soil organic matter. *Soil Science*. **109** (5): 332.  
Doi: <https://doi.org/10.1097/00010694-197005000-00011>
  12. Kuster, E. 1972. Simple working key for the classification and identification of named taxa involved in the international Streptomyces project. *Int. J. Syst. Bacteriol.* **22**: 139-148.  
Doi: <https://doi.org/10.1099/00207713-22-3-139>
  13. Kuzner, H. J. 1968. Über die bildung von huminstoffen durch streptomycetes. *Landwirtsch Forsch.* **21**: 48-61.
  14. Huntjens, J. L. M. 1972. Amino acid composition of humic acid like polymers produced by streptomycetes and of humic acids from pasture & arable land. *Soil Biol. Biochem.* **4**: 339-345.  
Doi: [https://doi.org/10.1016/0038-0717\(72\)90030-2](https://doi.org/10.1016/0038-0717(72)90030-2)
  15. McCarthy, A.J. 1987. Lignocellulose-degrading actinomycetes. *FEMS Microbiol Rev.* **46**: 145-163.  
Doi: [https://doi.org/10.1016/0378-1097\(87\)90061-9](https://doi.org/10.1016/0378-1097(87)90061-9)
  16. Crawford, D. L. & Donnelly P. K. 1988. Production by Streptomyces viridosporus T7A of an enzyme which cleaves aromatic acids from lignocellulose. *Appl Environ Microbiol.* **54**(9): 2237-2244.  
Doi: <https://doi.org/10.1128/aem.54.9.2237-2244.1988>
  17. Wang, Y., Zhang, Z. S., Ruan, J. S., Wang, Y. M. and Ali, S. M. 1991. Investigation of actinomycetes diversity in the tropical rainforest of Singapore. *Journal of Industrial Microbiology and Biotechnology.* **23**: 178-187.  
Doi: <https://doi.org/10.1038/sj.jim.2900723>
  18. Genilloud, O., González, I., Salazar, O., Martín, J., Tormo, J. R. & Vicente, F. 2011. Current approaches to exploit actinomycetes as a source of novel natural products. *Journal of industrial microbiology & biotechnology.* **38**(3): 375-389.  
Doi: <https://doi.org/10.1007/s10295-010-0882-7>
  19. Omura S. 1992. Thom Award Lecture. Trends in the search for bioactive microbial metabolites. *Journal of industrial microbiology.* **10**(3-4): 135-156.  
Doi: <https://doi.org/10.1007/bf01569759>
  20. Solecka, J., Zajko, J., Postek, M. & Rajnisz, A. 2012. Biologically active secondary metabolites from actinomycetes. *Open Life Sciences.* **7**(3): 373-390.  
Doi: <https://doi.org/10.2478/s11535-012-0036-1>
  21. Rainbow, C. & Rose, A. H. 1963. *Biochemistry of industrial microorganisms*. Academic Press, London and New York.
  22. Lilly, D. M. & Stillwell, R. H. 1965. Probiotics: growth-promoting factors produced by microorganisms. *Science.org.* **147** (3659): 747-748.  
Doi: <https://doi.org/10.1126/science.147.3659.747>
  23. Tiwari, K. & Gupta, R. K. 2011. Rare actinomycetes: a potential storehouse for novel antibiotics. *Critical Reviews in Biotechnology.* **32**(2): 108-132.  
Doi: <https://doi.org/10.3109/07388551.2011.562482>
  24. Waksman, S. A., Schatz, A. & Reynolds, D. M. 2010. Production of antibiotic substances by actinomycetes. *Annals of the New York Academy of Sciences.* **112**-124.  
Doi: <https://doi.org/10.1111/j.1749-6632.2010.05861.x>
  25. Magarvey, N. A., Keller, J. M., Berman, V., Dworkin, M. and Sherman, D. H. 2004. Isolation and characterization of novel marine-derived actinomycete taxa rich in bioactive metabolites. *Applied and environmental microbiology.* **70**:12.  
Doi: <https://doi.org/10.1128/aem.70.12.7520-7529.2004>
  26. Jensen, P. R., Dwight, R. and Fenical, W. 1991. Distribution of actinomycetes in near-shore tropical marine sediments. *Applied and environmental microbiology.* **57**(4): 1102-1108.  
Doi: <https://doi.org/10.1128/aem.57.4.1102-1108.1991>
  27. Hassan, A. A., El-Barawy, A. M. and El Mokhtar, M. N. 2011. Evaluation of biological compounds of Streptomyces species for control of some fungal diseases. *Am. J. Sci.* **7** (4): 752-760.
  28. Bérdy, J. 2005. Bioactive Microbial Metabolites. *The Journal of antibiotics.* **58**: 1-26.  
Doi: <https://doi.org/10.1038/ja.2005.1>
  29. Kurtboke, D. I. 2010. Biodiscovery from microbial resources: actinomycetes leading the way. *Microbiol. Aust.* **31**: 53-56.  
Doi: <https://doi.org/10.1071/ma10053>
  30. Chaudhary, H. S., Soni, B., Shrivastav, A. R. and Shrivastava, S. 2013. Diversity and versatility of actinomycetes and its role in antibiotic production. *Journal of Applied Pharmaceutical Science.* **3**(8): S83-S94.  
Doi: <https://doi.org/10.7324/japs.2013.38.s14>
  31. Kollef, M. H. 2009. New antimicrobial agents for methicillin-resistant Staphylococcus aureus. *Critical Care and Resuscitation.* **11**(4): 282-286.  
Doi: [https://doi.org/10.1016/s1441-2772\(23\)01290-5](https://doi.org/10.1016/s1441-2772(23)01290-5)
  32. Harvey, R. A. and Champe, P. C. 2009. *Lippincott's Illustrated Reviews: Pharmacology*. Fourth edition, Lippincott Williams and Wilkins, Philadelphia
  33. Nanjawade, B. K., Chandrashekhara, S., Shamarez, A. M., Prakash, S. G. and Fakirappa, V. M. 2010. Isolation and morphological characterization of antibiotic producing actinomycetes. *Trop J Pharm Res.* **9**: 231-236.

- Doi: <https://doi.org/10.4314/tjpr.v9i3.56282>
34. Floss, G. H. and Yu, T. W. 1999. Lesson from the rifamycin biosynthetic gene cluster. *Current Opinion in Chemical Biology*. **3**: 592-597  
Doi: [https://doi.org/10.1016/s1367-5931\(99\)00014-9](https://doi.org/10.1016/s1367-5931(99)00014-9)
  35. Kremer, L. C. M., Van Dalen, E. C., Offringa, M., Ottenkamp, J. & Voûte, P. A. 2001. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. *Journal of clinical oncology*. **19** (1): 191-196.  
Doi: <https://doi.org/10.1200/jco.2001.19.1.191>
  36. Xiao, X., Wolfe, S. and Demain, A. L. 1991. Purification and characterization of cephalosporin 7 $\alpha$ -hydroxylase from *Streptomyces clavuligerus*. *Biochem. J.* **280** (2): 471-474.  
Doi: <https://doi.org/10.1042/bj2800471>
  37. Grossman, T. H. 2016. Tetracycline antibiotics and resistance. *Cold Spring Harbor perspectives in medicine*. **6** (4): a025387.  
Doi: <https://doi.org/10.1101/cshperspect.a025387>
  38. Clark, R. B., Hunt, D. K., He, M., Achorn, C., Chen, C. L., Deng, Y., Fyfe, C., Grossman, T. H., Hogan, P. C., O'Brien, W. J., Plamondon, L., Rönn, M., Sutcliffe, J. A., Zhu, Z. & Xiao, X. Y. 2012. Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy. *J. Med. Chem.* **55**(2): 606-622.  
Doi: <https://doi.org/10.1021/jm201467r>
  39. Xiao, X. Y., Hunt, D. K., Zhou, J., Clark, R. B., Dunwoody, N., Fyfe, C., Grossman, T. H., O'Brien, W. J., Plamondon, L., Rönn, M., Sun, C., Zhang, W. Y. & Sutcliffe, J. A. 2012. Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. *J. Med. Chem.* **55**(2): 597-605.  
Doi: <https://doi.org/10.1021/jm201465w>
  40. Draper, M. P., Weir, S., Maccone, A., Donatelli, J., Trieber, C. A., Tanaka, S. K. and Levy, S. B. 2014. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. *Antimicrobial agents and chemotherapy*. **58**: 1279-1283  
Doi: <https://doi.org/10.1128/aac.01066-13>
  41. Daniel, T. M. 2005. Selman Abraham Waksman and the discovery of streptomycin. *The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease*. **9** (2): 120-122.  
Doi: [https://doi.org/10.1016/0962-8479\(95\)90548-0](https://doi.org/10.1016/0962-8479(95)90548-0)
  42. Ball, A. P., Gray, J. A. & Murdoch, J. M. 1975. *Antibacterial Drugs today: II. Drugs*. **10** (2): 81-111.  
Doi: <https://doi.org/10.2165/00003495-197510020-00001>
  43. Mitnick, C. D., McGee, B. & Peloquin, C. A. 2009. Tuberculosis pharmacotherapy: strategies to optimize patient care. *Expert opinion on pharmacotherapy*. **10** (3): 381-401.  
Doi: <https://doi.org/10.1517/14656560802694564>
  44. Sterling, T. R., Njie, G., Zenner, D., Cohn, D. L., Reves, R., Ahmed, A., Menzies, D., Horsburgh, C. R., Crane, C. M., Burgos, M., LoBue, P., Winston, C. A. and Belknap, R. 2020. Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC. *MMWR Recomm Rep*. **69** (1):1-11.  
Doi: <https://doi.org/10.15585/mmwr.r6901a1>
  45. Rothstein, D. M. 2016. Rifamycins, Alone and in Combination. *Cold Spring Harb Perspect Med*. **6** (7): a027011  
Doi: <https://doi.org/10.1101/cshperspect.a027011>
  46. Lo, D. K., Muhlebach, M. S. and Smyth, A. R. 2022. Interventions for the eradication of meticillin-resistant *Staphylococcus aureus* (MRSA) in people with cystic fibrosis. *Cochrane Database Syst Rev*. **12** (12): CD009650.  
Doi: <https://doi.org/10.1002/14651858.cd009650.pub5>
  47. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. and Gianni, L. 2004. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol Rev*. **56** (2):185-229.  
Doi: <https://doi.org/10.1124/pr.56.2.6>
  48. Megías-Vericat, J. E., Martínez-Cuadrón, D., Sanz, M. Á., Poveda, J. L. and Montesinos, P. 2019. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. *Expert Rev Clin Pharmacol*. **12**(3):197-218.  
Doi: <https://doi.org/10.1080/17512433.2019.1573668>
  49. Alqahtani, S. S., Moni, S. S., Sultan, M. H., Bakkari, M. A., Madkhali, O. A., Alshahrani, S., Makeen, H. A., Menachery, S. J., Rehman, Z. U., Alam, M. S., Mohan, S., Elmobark, M. E., Banji, D. and Sayed-Ahmed, M. Z. 2022. Potential bioactive secondary metabolites of actinomycetes sp. isolated from rocky soils of the heritage village Rijal Alma, Saudi Arabia. *Arabian J. Chem.* **15**(5):103793.  
Doi: <https://doi.org/10.1016/j.arabjc.2022.103793>
  50. Baltz, R. H. 2009. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. *Curr Opin Chem Biol*. **13**(2):144-151.  
Doi: <https://doi.org/10.1016/j.cbpa.2009.02.031>
  51. Maiti, P. K., Das, S., Sahoo, P. & Mandal, S. 2020. *Streptomyces* sp SM01 isolated from Indian soil produces a novel antibiotic picolinamycin effective against multi drug resistant bacterial strains. *Scientific reports*. **10**(1):10092.  
Doi: <https://doi.org/10.1038/s41598-020-66984-w>
  52. Tian, H., Shafi, J., Ji, M., Bi, Y. & Yu, Z. 2017. Antimicrobial metabolites from *Streptomyces* sp. *SN0280*. *J. Nad. Prod.* **80**(4): 1015-1019.  
Doi: <https://doi.org/10.1021/acs.jnatprod.6b01016>
  53. Bérdy, J. 2005. Bioactive microbial metabolites: a personal view. *J Antibiot*. **58**:1-26.  
Doi: <https://doi.org/10.1038/ja.2005.1>
  54. Guan, X., Li, W., Liu, C., Jin, P., Guo, S., Wang, X. and Xiang, W. 2016. *Streptomyces songpinggouensis* sp. nov., a Novel actinomycete Isolated from soil in Sichuan. *China Curr Microbiol*. **73**:796-801.  
Doi: <https://doi.org/10.1007/s00284-016-1128-3>

55. Gopalakrishnan, S., Sharma, R., Srinivas, V., Naresh, N., Mishra, S. P., Ankati, S., Pratyusha, S., Govindaraj, M., Gonzalez, S. V., Nervik, S. & Simic, N. 2020. Identification and characterization of a *Streptomyces albus* Strain and its secondary metabolite organophosphate against charcoal rot of sorghum. *Plants*. **9**(12): 1727.  
Doi: <https://doi.org/10.3390/plants9121727>
56. Vicente Dos Reis, G., Abraham, W. R., Grigoletto, D. F., de Campos, J. B., Marcon, J., da Silva, J. A., Quecine, M. C., de Azevedo, J. L., Ferreira, A. G. & de Lira, S. P. 2019. Gloeosporiocide, a new antifungal cyclic peptide from *Streptomyces morookaense* AM25 isolated from the Amazon bulk soil. *FEMS Microbiol. Lett.* **366**(14): 175.  
Doi: <https://doi.org/10.1093/femsle/fnz175>
57. Han, Y., Wang, Y., Yang, Y. & Chen, H. 2020. Shellmycin a-d, novel bioactive tetrahydroanthra- $\gamma$ -pyrone antibiotics from marine *Streptomyces* sp. shell-016. *Marine Drugs*. **18**(1): 58.  
Doi: <https://doi.org/10.3390/md18010058>
58. Pournejati, R., Gust, R., Kircher, B., & Karbalaee-Heidari, H. R. 2020. Microindoline 581, an indole derivative from *Microbacterium* Sp. RP581 as a novel selective antineoplastic agent to combat hepatic cancer cells: production, optimization and structural elucidation. *IJPR*. **19**(4): 290–305.  
Doi: <https://doi.org/10.1016/j.tiv.2021.105148>
59. Berezin, V., Abdulkhakimova, D., Trenzchnikova, L., Bogoyavlenskiy, A., Turmagambetova, A., Issanov, A. and Azizan, A. 2019. Antiviral activities of extremophilic actinomycetes extracts from Kazakhstan's unique ecosystems against influenza viruses and paramyxoviruses. *Virol J.* **16**:150.  
Doi: <https://doi.org/10.1186/s12985-019-1254-1>
60. Fang, Y., Wang, J., Tang, Y., Guo, Z., Bai, J., Wu, L., Su, J., Cen, S., Yu, L. & Zhang, D. 2023. Geninthiocins E and F, two new cyclic thiopeptides with antiviral activities from soil-derived *Streptomyces* sp. CPCC 200267 using OSMAC strategy. *J. Antibiot.* **76**(2): 101–104.  
Doi: <https://doi.org/10.1038/s41429-022-00580-0>
61. Kimura, T., Suga, T., Kameoka, M., Ueno, M., Inahashi, Y., Matsuo, H., Iwatsuki, M., Shigemura, K., Shiomi, K., Takahashi, Y., Ōmura, S. & Nakashima, T. 2019. New tetrahydroquinoline and indoline compounds containing a hydroxy cyclopentenone, virantmycin B and C, produced by *Streptomyces* sp. AM-2504. *The Journal of antibiotics*. **72**(3): 169–173.  
Doi: <https://doi.org/10.1038/s41429-018-0117-0>
62. Cheng, C., MacIntyre, L., Abdelmohsen, U. R., Horn, H., Polymenakou, P. N., Edrada-Ebel, R. A. and Hentschel, U. 2015. Biodiversity, antitrypanosomal activity screening, and metabolomic profiling of actinomycetes isolated from Mediterranean sponges. *PLoS ONE*. **10** (9): e0138528.  
Doi: <https://doi.org/10.1371/journal.pone.0138528>
63. Ruwandeeepika, H. A. D., Fernando, G. C. P. and Jayaweera, T. S. P. 2022. An overview of biomedical, biotechnological, and industrial applications of actinomycetes. In: Rai RV, Bai JA (eds) *Natural Products from Actinomycetes*. Springer, Singapore.
64. Gao, C., Guo, Z., Lu, X., Chen, H., Liu, L., Yu, Z. and Chen, H. 2018. Hexaricins, pradimicin-like polyketides from a marine sediment-derived *Streptosporangium* sp. and their antioxidant effects. *J Nat Prod.* **81**(9): 2069–2074.  
Doi: <https://doi.org/10.1021/acs.jnatprod.8b00397>
65. Nazari, M. T., Machado, B. S., Marchezi, G., Crestani, L., Ferrari, V., Colla, L. M. and Piccin, J. S. 2022. Use of soil actinomycetes for pharmaceutical, food, agricultural, and environmental purposes. *3 Biotech.* **12**(9): 232.  
Doi: <https://doi.org/10.1007/s13205-022-03307-y>
66. Mukhtar, S., Zaheer, A., Aiysha, D., Malik, K.A. and Mehnaz, S. 2017. Actinomycetes: a source of industrially important enzymes. *J Proteomics Bioinf.* **10**(12): 316–319.  
Doi: <https://doi.org/10.4172/jpb.1000456>
67. Sonia, M. T., Hafedh, B., Abdennaceur, H. and Ali, G. 2011. Studies on the ecology of actinomycetes in an agricultural soil amended with organic residues: II. assessment of enzymatic activities of Actinomycetales isolates. *World J Microbiol Biotechnol.* **27**: 2251–2259.  
Doi: <https://doi.org/10.1007/s11274-011-0688-4>
68. Wu, H., Liu, B., Ou, X., Pan, S., Shao, Y. and Huang, F. 2018. *Streptomyces thermoalkaliphilus* sp. nov., an alkaline cellulase producing thermophilic actinomycete isolated from tropical rainforest soil. *Antonie Van Leeuwenhoek.* **111**: 413–422.  
Doi: <https://doi.org/10.1007/s10482-017-0964-x>
69. Salgado, C. A., Santos, C. I. A. and Vanetti, M. C. D. 2022. Microbial lipases: propitious biocatalysts for the food industry. *Food Biosci.* **45**: 101509.  
Doi: <https://doi.org/10.1016/j.fbio.2021.101509>
70. Kirk, O., Borchert, T. V. and Fuglsang, C. C. 2002. Industrial enzyme applications. *Curr Opin Biotechnol.* **13**(4): 345–351.  
Doi: [https://doi.org/10.1016/s0958-1669\(02\)00328-2](https://doi.org/10.1016/s0958-1669(02)00328-2)
71. Haneen, M. A., Jayashankar, M. and Swamy, V. N. 2022. Screening of pectinase from actinobacteria. in: Dharumadurai D (ed) *methods in actinobacteriology*. Humana Press, New York.
72. Narayana, K. J. P., Kumar, K. G. and Vijayalakshmi, M. 2007. L-asparaginase production by *Streptomyces albidoflavus*. *Indian J. Microbiol.* **48** (3): 331-336.  
Doi: <https://doi.org/10.1007/s12088-008-0018-1>
73. Charousová, I., Medo, J., Halenářová, E. & Javoreková, S. 2017. Antimicrobial and enzymatic activity of actinomycetes isolated from soils of coastal islands. *J. Adv Pharm. Technol. Res.* **8**(2): 46–51.  
Doi: [https://doi.org/10.4103/japtr.japtr\\_161\\_16](https://doi.org/10.4103/japtr.japtr_161_16)
74. Sharma, M. Dangi, P. and Choudhary, M. 2014. Actinomycetes: source, identification and their applications. *Int. J. Curr. Microbiol. App. Sci.* **3**: 801-832.
75. AbdElgawad, H., Abuelsoud, W., Madany, M. M.Y., Selim, S., Zinta, G., Mousa, A. S. M. and Hozzein, W. N. 2020. Actinomycetes enrich soil rhizosphere and improve seed quality as well as productivity of legumes by boosting nitrogen availability and metabolism. *Biomolecules.* **10**: 1675.  
Doi: <https://doi.org/10.3390/biom10121675>

76. Asadu, C. O., Ike, I. S., Onu, C. E., Egbuna, S. O., Onoh, M., Mbah, G. O. & Eze, C. N. 2020. Investigation of the influence of biofertilizer synthesized using microbial inoculums on the growth performance of two agricultural crops. *Biotechnology reports*. **27**: 00493  
Doi: <https://doi.org/10.1016/j.btre.2020.e00493>
77. Marin-Bruzos, M., Grayston, S. J., Forge, T. and Nelson, L. M. 2021. Isolation and characterization of streptomycetes and pseudomonad strains with antagonistic activity against the plant parasitic nematode *Pratylenchus penetrans* and fungi associated with replant disease. *Biol Control*. **158** (1): 104599.  
Doi: <https://doi.org/10.1016/j.biocontrol.2021.104599>
78. Arora, N.K. and Bouizgarne, B. 2022. *Microbial biotechnology for sustainable agriculture*. First edition, Springer, Singapore.
79. Singh, S. and Nain, L. 2014. Microorganisms in the conversion of agricultural wastes to compost. *In Proc. Indian Natn. Sci. Acad.* **80**: 473 - 481.  
Doi: <https://doi.org/10.16943/ptinsa/2014/v80i2/4>
80. Kucey, R. M. N., Janzen, H. H. and Legett, M. E. 1989. Microbial mediated increases in plant-available phosphorus. *Adv. Agro.* **42**: 198-228.  
Doi: [https://doi.org/10.1016/s0065-2113\(08\)60525-8](https://doi.org/10.1016/s0065-2113(08)60525-8)
81. Jose, P. A. and Jha, B. 2016. New dimensions of research on actinomycetes: quest for next generation antibiotics. *Front. Microbiol.* **7**: 1295.  
Doi: <https://doi.org/10.3389/fmicb.2016.01295>
82. Braun, V., Hantke, K. & Köster, W. 1998. Bacterial iron transport: mechanisms, genetics, and regulation. *Metal ions in biological systems*. **35**: 67–145.
83. Kaur, T., Sharma, D., Kaur, A. and Manhas, R. K. 2013. Antagonistic and plant growth promoting activities of endophytic and soil actinomycetes. *Arch Phitopathol Plant Prot.* **46** (10): 1080.  
Doi: <https://doi.org/10.1080/03235408.2013.777169>
84. Sundarapandian, S., Sundaram, M. D., Tholkappian, P. and Balasubramanian, V. 2002. Mosquitocidal properties of indigenous fungi and actinomycetes against *Culex quinquefasciatus* say. *J Biol Control*. **16**: 89–91.  
Doi: <https://doi.org/10.1590/1519-6984.248122>
85. Khucharoenphaisan, K., Rodbangpong, K., Saengpaen, P. and Sinma, K. 2016. Exploration on soil actinomycetes against *Phytophthora* sp. causing root rot of cassava and plant growth promoting activities. *J Plant Sci.* **11**: 38–44.  
Doi: <https://doi.org/10.3923/jps.2016.38.44>
86. Bhosale, H. J., Kadam, T. A., Mirajgave, R. S. and Holkar, S. K. 2018. Optimization and characterization of antifungal metabolite from a soil actinomycete *Streptomyces indiaensis* SRT1. *Indian J Biotechnol.* **17**: 261–271.
87. Daquioag, J. E., Penuliar, G. M. 2021. Isolation of actinomycetes with cellulolytic and antimicrobial activities from soils collected from an urban green space in the Philippines. *Int J Microbiol.* **2021**(1): 6699430.  
Doi: <https://doi.org/10.1155/2021/6699430>
88. Al-Maliki, S., Al-Amery, A., Sallal, M., Radhi, A. and Al-Taey, D. K. A. 2021. Effects of arbuscular mycorrhiza and organic wastes on soil carbon mineralisation, actinomycetes and nutrient content in maize plants (*Zea mays* L.). *Malaysian J Soil Sci.* **25**: 107–124.
89. Cheng, C., Chen, L., Guo, K., Xie, J., Shu, Y., He, S. and Xiao, F. 2022. Progress of uranium-contaminated soil bioremediation technology. *J Environ Radioact.* **241**: 106773.  
Doi: <https://doi.org/10.1016/j.jenvrad.2021.106773>
90. Aparicio, J. D., Raimondo, E. E., Gil, R. A., Benimeli, C. S. and Polti, M. A. 2018a. Actinobacteria consortium as an efficient biotechnological tool for mixed polluted soil reclamation: experimental factorial design for bioremediation process optimization. *J Hazard Mater.* **342**: 408–417.  
Doi: <https://doi.org/10.1016/j.jhazmat.2017.08.041>
91. Hamed, J., Dehghani, M. and Mohammadpanah, F. 2015a. Isolation of extremely heavy metal resistant strains of rare actinomycetes from high metal content soils in Iran. *Int J Environ Res.* **9**(2): 475–480.
92. Chuang, S., Yang, H., Wang, X., Xue, C., Jiang, J. and Hong, Q. 2021. Potential effects of *Rhodococcus qingshengii* strain dj1-6 on the bioremediation of carbendazim-contaminated soil and the assembly of its microbiome. *J Hazard Mater.* **414**: 125496  
Doi: <https://doi.org/10.1016/j.jhazmat.2021.125496>
93. Thompson, C. J., Fink, D. and Nguyen, L. D. 2002. Principles of microbial alchemy: insights from the *Streptomyces coelicolor* genome sequence. *Genome Biol.* **3**(7): 1020.1–1020.4.
94. Moore, B. S., Trischman, J. A., Seng, D., Kho, D., Jensen, P. R. and Fenical, W. 1999. Salinamides, antiinflammatory depsipeptides from a marine streptomycete. *J Organomet Chem.* **64**(4): 1145–1150.  
Doi: <https://doi.org/10.1021/jo9814391>
95. Sathi, Z. S., Sugimoto, N., Khalil, M. I. and Gafur, M. A. 2002. Isolation of yellowish antibiotic pigment 4-hydroxy nitrobenzene from a strain of *Streptomyces*. *Pak J Biol Sci.* **52**(2): 201–203.  
Doi: <https://doi.org/10.3923/pjbs.2002.201.203>
96. El-Sheekh, M. M., Allam, N. G., Shabana, S. A. and Azab, M. M. 2017. Efficiency of lipid accumulating Actinomycetes isolated from soil for biodiesel production: comparative study with microalgae. *Energy Sources A.* **39**(9): 883–892.  
Doi: <https://doi.org/10.1080/15567036.2016.1273279>

